long intergenic non-protein coding RNA 616Genealiases: []
Q-omics provides the consensus-scored LINC00616 profile across patient tissues and cancer cell-line models. LINC00616 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, LINC00616 is differentially expressed in 2, with the highest sampling consensus in PAAD. Additionally, LINC00616 RNA expression shows 6,638 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THYM, PAAD, and TGCT as cancer lineages where LINC00616 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00616 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00616 survival associations across molecular data types. LINC00616 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00616 RNA expression–survival associations across cancer types. High LINC00616 expression shows unfavorable associations in THYM, ACC, LIHC, KICH, LUAD and OV. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for LINC00616 RNA expression.
This table summarizes LINC00616 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00616. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00616 shows higher tumor expression in PAAD and UCEC. The PAAD box plot shows higher LINC00616 RNA expression in tumor versus normal tissue (log2 FC = +0.212, t-test p = .023).
This table shows molecular features associated with LINC00616 in patient tissues and cancer cell lines. In patient samples, LINC00616 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
